Patents by Inventor Michael Alan Green

Michael Alan Green has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS
    Publication number: 20240140948
    Abstract: The present invention is directed to inhibitors of Kirsten Rat sarcoma virus (KRAS), and more particularly to compounds of Formula I as well as compositions comprising Formula I and methods of using the compound of Formula I for the treatment or prevention of a disease, disorder, or medical condition mediated through KRAS, especially the KRAS mutant G12C.
    Type: Application
    Filed: March 9, 2022
    Publication date: May 2, 2024
    Inventors: Don Zhang, Jirong Peng, Michael John Costanzo, Michael Alan Green, Michael Nicholas Greco, Stephen Bolgunas
  • PYRIDAZINE AND 1,2,4-TRIAZINE DERIVATIVES AS FGFR KINASE INHIBITORS
    Publication number: 20240002365
    Abstract: The present invention is directed to inhibitors of fibroblast growth factors, and more particularly to compounds of Formula (I), as well as compositions comprising Formula (I) and methods of using the compound of Formula (I) for the treatment or prevention of a disease, disorder, or medical condition mediated through the fibroblast growth factor receptor (FGFR), especially FGFR1-4. These diseases, disorders, or medical conditions include various cancers.
    Type: Application
    Filed: January 12, 2021
    Publication date: January 4, 2024
    Inventors: Don Zhang, Jirong Peng, Michael John Costanzo, Michael Alan Green, Michael Nicholas Greco
  • PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS
    Publication number: 20230099858
    Abstract: The present invention is directed to inhibitors of Kirsten Rat sacoma virus (KRAS), and more particularly to compounds of Formula (I), as well as compositions comprising Formula I and methods of using the compound of Formula I for the treatment or prevention of a disease, disorder, or medical condition mediated through KRAS, especially the KRAS mutant G12C.
    Type: Application
    Filed: February 19, 2021
    Publication date: March 30, 2023
    Inventors: Don Zhang, Jirong Peng, Michael John Costanzo, Michael Alan Green, Michael Nicholas Greco
  • TREATMENT OF EGFR MUTANT-RELATED CANCERS USING A COMBINATION OF EGFR AND CDK4/6 INHIBITORS
    Publication number: 20220347177
    Abstract: Methods of treating EGFR mutant-related cancers with a combination of an EGFR inhibitor of Formula (I) and the CDK4/6 inhibitor of Formula (II) and use of combinations of these compounds in the manufacture of medicaments for the treatment of EGFR mutant-related cancers are disclosed:
    Type: Application
    Filed: September 23, 2020
    Publication date: November 3, 2022
    Inventors: Michael Nicholas Greco, Michael John Costanzo, Michael Alan Green, Don Zhang, Jirong Peng
  • Substituted 2-anilinopyrimidine derivatives as EGFR modulators
    Patent number: 11414401
    Abstract: This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: August 16, 2022
    Assignees: BETA PHARMA INC., BETA PHARMA (SHANGHAI) CO., LTD.
    Inventors: Jirong Peng, Michael John Costanzo, Michael Nicholas Greco, Michael Alan Green, Victoria Lynn Wilde, Don Zhang
  • PHARMACEUTICAL FORMULATIONS OF N-(2-(2-(DIMETHYLAMINO)ETHOXY)-4-METHOXY-5-((4-(1-METHYL-1H-INDOL-3-YL)PYRIMIDIN-2-YL)AMINO)PHENYL)ACRYLAMINDE AND SALTS THEREOF
    Publication number: 20220153726
    Abstract: A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharmaceutical formulation for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGER), such as various cancers, are disclosed.
    Type: Application
    Filed: November 12, 2021
    Publication date: May 19, 2022
    Inventors: Michael Nicholas Greco, Michael John Costanzo, Michael Alan Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF
    Publication number: 20220064194
    Abstract: The present disclosure provides [1,2,4]triazolo[4,3-b][1,2,4]triazine, [1,2,4] triazolo[4,3-b]pyridazine, and [1,2,3]triazolo[4,5-b]pyrazine derivatives, and pharmaceutically acceptable salts, solvates or prodrugs thereof, as tyrosine kinase c-MET inhibitors, which are useful as novel anticancer and/or anti-inflammatory agents.
    Type: Application
    Filed: December 14, 2019
    Publication date: March 3, 2022
    Inventors: Don ZHANG, Jirong PENG, Michael Nicholas GRECO, Michael John COSTANZO, Michael Alan GREEN
  • Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
    Patent number: 11180478
    Abstract: A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharmaceutical formulation for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 23, 2021
    Assignee: BETA PHARMA, INC.
    Inventors: Michael Nicholas Greco, Michael John Costanzo, Michael Alan Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
    Patent number: 11052086
    Abstract: Methods of using substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, or compositions, for the treatment of brain cancers, in particular EGFR-mediated metastatic brain cancer, are disclosed.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: July 6, 2021
    Assignee: BETA PHARMA, INC.
    Inventors: Michael Nicholas Greco, Michael John Costanzo, Michael Alan Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS
    Publication number: 20200216421
    Abstract: This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Applicants: Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd.
    Inventors: Jirong Peng, Michael John Costanzo, Michael Nicholas Greco, Michael Alan Green, Victoria Lynn Wilde, Don Zhang
  • PHARMACEUTICAL FORMULATIONS OF N-(2-(2-(DIMETHYLAMINO) ETHOXY)-4-METHOXY-5-((4-(1-METHYL-1H-INDOL -3-YL)PYRIMIDIN-2-YL)AMINO)PHENYL)ACRYLAMIDE AND SALTS THEREOF
    Publication number: 20200131152
    Abstract: A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharmaceutical formulation for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.
    Type: Application
    Filed: June 15, 2018
    Publication date: April 30, 2020
    Applicant: Beta Pharma, Inc.
    Inventors: Michael Nicholas Greco, Michael John Costanzo, Michael Alan Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • Substituted 2-anilinopyrimidine derivatives as EGFR modulators
    Patent number: 10590111
    Abstract: This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: March 17, 2020
    Assignee: Beta Pharma, Inc.
    Inventors: Jirong Peng, Michael John Costanzo, Michael Nicholas Greco, Michael Alan Green, Victoria Lynn Wilde, Don Zhang
  • 2-ANILINOPYRIMIDINE DERIVATIVES AS THERAPEUTIC AGENTS FOR TREATMENT OF BRAIN CANCERS
    Publication number: 20190365755
    Abstract: Methods of using substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, or compositions, for the treatment of brain cancers, in particular EGFR-mediated metastatic brain cancer, are disclosed.
    Type: Application
    Filed: May 11, 2017
    Publication date: December 5, 2019
    Applicant: Beta Pharma, Inc.
    Inventors: Michael Nicholas Greco, Michael John Costanzo, Michael Alan Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
    Patent number: 9862724
    Abstract: Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: January 9, 2018
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventors: Yingzhi Bi, Michael Walter Gardyan, Michael Alan Green, Godwin Kumi, Yulian Zhang
  • SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS
    Publication number: 20170362203
    Abstract: This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.
    Type: Application
    Filed: December 11, 2015
    Publication date: December 21, 2017
    Applicants: Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd.
    Inventors: Jirong Peng, Michael John Costanzo, Michael Nicholas Greco, Michael Alan Green, Victoria Lynn Wilde, Don Zhang
  • PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
    Publication number: 20170129896
    Abstract: Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.
    Type: Application
    Filed: July 12, 2016
    Publication date: May 11, 2017
    Inventors: Yingzhi BI, Kenneth Gordon CARSON, Giovanni CIANCHETTA, Michael Alan GREEN, Godwin KUMI, Alan MAIN, Yulian ZHANG, Glenn Gregory ZIPP
  • PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
    Publication number: 20170081330
    Abstract: Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.
    Type: Application
    Filed: May 3, 2016
    Publication date: March 23, 2017
    Inventors: Yingzhi BI, Michael Walter GARDYAN, Michael Alan GREEN, Godwin KUMI, Yulian ZHANG
  • IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
    Publication number: 20170057964
    Abstract: Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.
    Type: Application
    Filed: April 26, 2016
    Publication date: March 2, 2017
    Inventors: Yingzhi BI, Kenneth Gordon CARSON, Giovanni CIANCHETTA, Michael Alan GREEN, Godwin KUMI, Zhi LIANG, Ying Jade LIU, Alan MAIN, Yulian ZHANG, Glenn Gregory ZIPP
  • Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
    Patent number: 9403832
    Abstract: Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by adaptor associated kinase 1 activity are also disclosed.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: August 2, 2016
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventors: Yingzhi Bi, Kenneth Gordon Carson, Giovanni Cianchetta, Michael Alan Green, Godwin Kumi, Alan Main, Yulian Zhang, Glenn Gregory Zipp
  • IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
    Publication number: 20160024093
    Abstract: Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.
    Type: Application
    Filed: February 25, 2015
    Publication date: January 28, 2016
    Inventors: Yingzhi BI, Kenneth Gordon CARSON, Giovanni CIANCHETTA, Michael Alan GREEN, Godwin KUMI, Zhi LIANG, Ying Jade LIU, Alan MAIN, Yulian ZHANG, Glenn Gregory ZIPP